Availability of point-of-care HBV tests in resource-limited settings

Daryl T Y Lau¹, Kathy Jackson², Camila A Picchio³, Anna Kramvis⁴, Mark Sonderup⁵, Maud Lemoine⁶, Gail Matthews⁷, Jessica Howell⁸, Carla S Coffin⁹, Margaret Hellard¹⁰, Alice U Lee¹¹, David A Anderson¹², Helene A Kerth¹³, El Eunyoung Lee¹⁴, John E Tavis¹⁵, Maura Dandri¹⁶, Peter A Revill¹⁷, C Wendy Spearman⁵, Capucine Penicaud¹⁸, Massimo Levrero¹⁹, Manal El-Sayed²⁰; ICE-HBV POC Model in Resource Limited Settings working group

Affiliations

¹ Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: dlau@bidmc.harvard.edu.
² Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
³ Barcelona Institute for Global (3)Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain; Department of Community Health & Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
⁴ Hepatitis Virus Diversity Research Unit, Department of Internal Medicine, University of the Witwatersrand, South Africa.
⁵ Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
⁶ Division of Digestive Diseases, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK.
⁷ The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
⁸ Department of Gastroenterology, Burnet Institute, Melbourne, VIC, Australia; Burnet Institute, Melbourne, VIC, Australia.
⁹ Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
¹⁰ Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.
¹¹ University of Sydney, Concord Repatriation General Hospital, Department of Gastroenterology and Liver Services, Concord, NSW, Australia.
¹² Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC, Australia.
¹³ Institute of Virology, Technical University of Munich/Helmholtz Zentrum München, Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.
¹⁴ EXCOLO PTE LTD, Singapore.
¹⁵ Department of Molecular Microbiology and Immunology, St Louis University School of Medicine, St Louis, MI, USA.
¹⁶ University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Partner Site, Hamburg, Germany.
¹⁷ Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Department of Infectious Diseases, The University of Melbourne, Melbourne, VIC, Australia.
¹⁸ The Hepatitis Fund, Geneva, Switzerland.
¹⁹ Université Claude Bernard Lyon, Hospital de la Croix-Rousse, Lyon, France.
²⁰ Department of Pediatrics and Faculty of Medicine Ain Shams University Research Institute (MASRI), Ain Shams University, Cairo, Egypt.

PMID: 39305916
DOI: 10.1016/S2468-1253(24)00308-X

Availability of point-of-care HBV tests in resource-limited settings

Daryl T Y Lau et al. Lancet Gastroenterol Hepatol. 2024 Dec.

. 2024 Dec;9(12):1073-1076.

doi: 10.1016/S2468-1253(24)00308-X. Epub 2024 Sep 19.

Authors

Affiliations

¹ Liver Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. Electronic address: dlau@bidmc.harvard.edu.
² Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
³ Barcelona Institute for Global (3)Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain; Department of Community Health & Prevention, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
⁴ Hepatitis Virus Diversity Research Unit, Department of Internal Medicine, University of the Witwatersrand, South Africa.
⁵ Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.
⁶ Division of Digestive Diseases, Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK.
⁷ The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
⁸ Department of Gastroenterology, Burnet Institute, Melbourne, VIC, Australia; Burnet Institute, Melbourne, VIC, Australia.
⁹ Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
¹⁰ Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia.
¹¹ University of Sydney, Concord Repatriation General Hospital, Department of Gastroenterology and Liver Services, Concord, NSW, Australia.
¹² Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, VIC, Australia.
¹³ Institute of Virology, Technical University of Munich/Helmholtz Zentrum München, Munich, Germany; German Center for Infection Research (DZIF), Munich Partner Site, Munich, Germany.
¹⁴ EXCOLO PTE LTD, Singapore.
¹⁵ Department of Molecular Microbiology and Immunology, St Louis University School of Medicine, St Louis, MI, USA.
¹⁶ University Medical Center Hamburg-Eppendorf, Hamburg, Germany; German Center for Infection Research (DZIF), Hamburg-Lübeck-Borstel-Riems Partner Site, Hamburg, Germany.
¹⁷ Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia; Department of Infectious Diseases, The University of Melbourne, Melbourne, VIC, Australia.
¹⁸ The Hepatitis Fund, Geneva, Switzerland.
¹⁹ Université Claude Bernard Lyon, Hospital de la Croix-Rousse, Lyon, France.
²⁰ Department of Pediatrics and Faculty of Medicine Ain Shams University Research Institute (MASRI), Ain Shams University, Cairo, Egypt.

PMID: 39305916
DOI: 10.1016/S2468-1253(24)00308-X

No abstract available

PubMed Disclaimer

Conflict of interest statement

DTYL reports support from ICE HBV for travel to present this work at COLDA 2023. AK reports grants from CANSA Cancer Association of South Africa, consulting fees from Roche Diagnostics, and support for attending meetings from Virology Education, University of Witwatersrand, and WHO. MLem reports consulting fees from Abbott and honoraria from Cepheid for lectures and presentations. GM reports grants from ViiV and Jannsen. CSC reports grants from GSK, Gilead Sciences, Janssen, and Roche Pharmaceuticals, and has participated in a data safety monitoring board for GSK. MH reports grants from Gilead Sciences and AbbVie. DAA reports being an inventor on Burnet Institute patents for alanine aminotransferase point of care tests for liver disease (PCT/IB2017/055943) and for dimeric IgA point of care tests for liver cirrhosis (PCT/AU2021/050037), and stock in Nanjing DeShi Diagnostic Technology Co. Ltd, which has licensed the alanine aminotransferase point-of-care test patents from Burnet Institute for manufacture and sale in China. PAR reports grants from NHMRC and a patent pending for CRISPR Cas13b guides targeting HBV (2023901165). CWS reports support by Gilead Sciences to attend AASLD. MLev reports honoraria from AbbVie and Gilead for lectures and presentations and support for attending meetings from AbbVie, Madrigal, and Gilead. ME-S reports support by Gilead Sciences. All other authors declared no competing interests.

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Availability of point-of-care HBV tests in resource-limited settings

Affiliations

Availability of point-of-care HBV tests in resource-limited settings

Authors

Affiliations

Conflict of interest statement

LinkOut - more resources

Full Text Sources